Microcarriers Market to Hit USD 3.05 Billion by 2029 with 8.0% CAGR
"Key players in the microcarriers market include Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Sartorius AG (Germany), Corning Incorporated (US), FUJIFILM Holdings Corporation (Japan), BD (US), Eppendorf SE (Germany), Lonza (Switzerland)"
Browse 761 market data Tables and 57 Figures spread through 557 Pages and in-depth TOC on "Microcarriers Market by Product (Equipment (Single Use Bioreactor, SSB, Cell Counter, Filtration), Consumables (Media, Reagent), Beads (Natural (Collagen), Synthetic (Polystyrene)), Application (Vaccine, CGT, Stem Cells) - Global Forecast to 2029
The global Microcarriers market, valued at US$2.03 billion in 2023, is forecasted to grow at a robust CAGR of 8.0%, reaching US$2.08 billion in 2024 and an impressive US$3.05 billion by 2029. Market growth is attributed to rising investments in cell & gene therapy research, growing preference for single-use technologies, and increasing R&D spending for biopharmaceutical production. However, the high cost of cell biology research and limitations in high-density cell culture production are expected to hinder the market growth over the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139831731
Browse in-depth TOC on " Microcarriers Market"
761 - Tables
57 - Figures
557 - Pages
Based on product, the microcarriers market is segmented into consumables and equipment. The consumables segment accounted for the largest share of the microcarriers market. The large share of the consumables segment is attributed to the repeated purchase and requirement in bulk quantities of sera, media, and reagents for various microcarrier cell culture applications. Additionally, increasing production and development of advanced biopharmaceuticals is driving the growth of the segment in microcarriers market.
Among application segment, the microcarriers market is segmented into tissue engineering and regenerative medicine, biopharmaceutical production, and other applications. The biopharmaceutical production segment accounted for the largest share of the microcarriers market. The large share of the biopharmaceutical production segment can be attributed to the commercial expansion of major pharmaceutical companies, growing regulatory approvals for cell culture-based vaccines, and increasing demand for monoclonal antibodies (mAbs).
Among end user segment, the microcarriers market is segmented into pharmaceutical & biotechnology companies, academic and research institutes, contract research organizations & contract manufacturing organizations, and cell banks. The pharmaceutical & biotechnology companies segment accounted for the largest share of the microcarriers market. Rising awareness about the benefits of cell-based vaccines, growing regulatory approvals for cell-based vaccines, and a focus on commercial expansion are the major factors driving the growth of this segment.
The microcarriers market is segmented by region into six key areas, namely North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2023, North America dominated the market followed by Europe at second position and Asia Pacific was at third position. The majority share of the market in North America. The key factors driving the growth of the market in North America include increasing demand for cell-based therapies, strong government support for stem cell research, and the presence of a well-established pharmaceutical industry that is likely to drive the growth of the market. The market in Canada is likely to grow in the coming years due to several government initiatives and the intensification of genomics R&D through the Genomic Applications Partnership Program (GAPP) in the country.
In addition, the US accounted for the largest market share in the North American microcarriers market. Major share of the country is determined by factors like well-established pharmaceutical and biotechnology sector, cell therapy and biologics, and regulatory vaccine approvals. Increasing incidences of diseases like cancer along with high funding for the life sciences research are also contributing to the major share of the country. For example, According to the National Cancer Institute, there were nearly 2 million people who were suffering from US Cancer cases in 2023. The current treatment options will cater to the unmet demands if cell-based therapies are employed. Since microcarrier culture technology is used in the R&D and production of vaccines and antibiotics, it is likely that these factors will create a large number of opportunities for the growth of the microcarriers market.
Europe is the second largest market after North America. The availability of government funding, growth in the biotechnology and pharmaceutical sectors, and the rise in the number of conferences, symposia, seminars, trade fairs, annual events, and workshops being organized in Europe that focus on creating awareness about microcarriers are expected to drive the growth of the market in the region. These factors help increase awareness about current technological advancements and aid in the discussion of various challenges and opportunities prevailing in the industry. Such events also offer market players the opportunity to showcase their products and communicate with stakeholders while helping scientists and researchers to exchange experiences. According to the Alliance for Regenerative Medicine (ARM), a global advocate for regenerative and advanced therapies, out of 843 regenerative medicine companies globally, Europe houses 234.
Moreover, In 2023, the Asia Pacific is third largest market for microcarriers. This surge in the regional market is attributed to various factors such as government backing for cell-based vaccine production and therapies, expansion initiatives by key market players in emerging Asian economies, heightened vaccine manufacturing capacities of major companies, increased research and development investments by biotechnology and pharmaceutical firms, collaborative ventures in bioprocessing, a growing elderly population, amplified focus on regenerative medicine research, and the upsurge in preclinical/clinical research particularly in China and India.
Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Danaher Corporation (US) holding the significant global market share and the global microcarriers market is highly cosolidated.
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific (US) is a leading player in the microcarriers market. The company has strong brand image, robust product portfolio, and product development focus. The company offers its products through well-established brands such as Gibco, Nunc, Countess, Dynabeads, and HyPerforma. The company focuses on product launches, expansion, and acquisition to strengthen the position in the market. For example, in September 2023, the company introduced Gibco CTS Detachable Dynabeads, a groundbreaking platform with an innovative active-release mechanism designed for clinical and commercial cell therapy manufacturing.
Merck KGaA (Germany)
Merck KGaA is a leading science and technology company with a strong global presence in more than 120 countries. The company has a portfolio of more than 300,000 life science products that support a broad customer base. Merck has been a prominent player in the life sciences industry, offering various products and services to support researchers and biomanufacturers. The company has a comprehensive portfolio that includes cell culture media, reagents, and other essential tools for bioprocessing. Merck majorly focuses on expansions in key geographies to increase its customer base. In June 2023, Merck KGaA expanded its reagent manufacturing facility in Nantong, China with an investment of about USD 76.5 million.
Danaher Corporation (US)
Danaher Corporation is one of the leading companies in the microcarriers market, attributed to a strong product portfolio, recent acquisitions, and partnerships. Danaher Corporation (Cytiva) (US) offers a wide range of products, including microcarriers, bioreactors, media, and reagents, which greatly expanded Danaher's position and offerings in the microcarriers market. The Pall Corporation subsidiary is also active in this market and offers single-use and stainless-steel bioreactors and filtration equipment. In May 2023, Cytiva and the life sciences business of Pall Corporation completed their integration and are now united as one business under the Cytiva brand.
In October 2023, Cytiva opened a new manufacturing facility in Pune, India, which will double its manufacturing capacity in the country. The facility will produce bioprocessing equipment, including tangential flow, virus filtration, and inactivation systems, to support the Indian biopharmaceutical industry.
For more information, Inquire Now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
RTX's Arm Secures $300M Contract for ESSM Block II Missile Assemblies
RTX Corporation 's RTX business segment, Raytheon, recently secured a $299.7 million modification contract involving the Evolved Seasparrow Missile (ESSM). Per the terms of the deal, RTX will provide test equipment and spares, as well as exercise options for ESSM Block 2 guided missile assemblies. Details of RTX's Deal The work related to this contract will be executed in multiple locations globally, including the United States, Australia, Canada, Norway, the Netherlands and a few other nations. This contract is projected to be completed by September 2030. The award has been provided by the Naval Sea Systems Command, Washington, D.C. What's Favoring RTX? With countries worldwide enhancing their defense capabilities, spending on advanced military arms and ammunition has been rapidly increasing lately. This includes growing investments in missiles and missile systems, which are essential for modern warfare. RTX, as a prominent manufacturer of missile systems, has thus been witnessing a steady flow of orders from the Pentagon and other U.S. allies. The recent contract is an example of that. RTX's ESSM Block II is a versatile, combat-proven naval defense system with more than 330 successful live sea firings. Offering enhanced performance over Block I, it strengthens fleet protection against diverse threats. These advanced features likely drive its growing demand, reflected in the latest contract win. RTX's Growth Prospects Rising military conflicts, terrorism and border disputes have led nations to increase their focus on national security, particularly on missile defense systems in recent times, backed by the rapid development of advanced missile technologies over the last decade. This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 5% for the global missiles and missile defense systems market during the 2025-2030 time period. Such strong growth projections indicate solid opportunities for RTX, which has a handful of combat-proven missiles in its product portfolio, like the TOW missile, Guidance Enhanced Missile, Advanced Medium Range Air-to-Air Missile, Tomahawk, Standard Missile 2 and a few more, in addition to the ESSM. Opportunities for Other Defense Stocks Other defense companies that are likely to enjoy the perks of the expanding missiles and missile system market have been discussed below: Northrop Grumman NOC: Northrop Grumman provides high-speed, long-range strike weapons like the AARGM-ER, which is a supersonic, air-launched tactical missile system. It also builds advanced missile defense technology, ranging from command systems to directed energy weapons, advanced munitions and powerful sensors. The company's long-term (three to five years) earnings growth rate is 3.3%. The Zacks Consensus Estimate for NOC's 2025 sales indicates year-over-year growth of 2.8%. The Boeing Company BA: It manufactures various missile defense systems, including the Ground-based Midcourse Defense, Aegis Ballistic Missile Defense and Avenger. Boeing-built missile defense systems have been protecting its customers for nearly 25 years against threats ranging from intercontinental ballistic missiles to hostile aircraft. The company has a long-term earnings growth rate of 18.1%. The Zacks Consensus Estimate for BA's 2025 sales indicates year-over-year growth of 25.6%. Lockheed Martin LMT: Lockheed Martin's missile defense program includes the Patriot Advanced Capability-3 and Terminal High-Altitude Area Defense air and missile defense programs. It also manufactures the Multiple Launch Rocket System, the Joint Air-to-Surface Standoff Missile and Javelin tactical missiles. The company has a long-term earnings growth rate of 10.5%. The Zacks Consensus Estimate for LMT's 2025 sales indicates year-over-year growth of 4.7%. RTX Stock's Price Movement Shares of RTX have gained 25.1% in the past six months compared with the industry 's 15.5% growth. RTX's Zacks Rank RTX currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report Northrop Grumman Corporation (NOC): Free Stock Analysis Report RTX Corporation (RTX): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
26 minutes ago
- Globe and Mail
From Anywhere to Anywhere: Elife Group Unveils its Multi-Modal Platform with Train and Ride-Hailing
SAN FRANCISCO & LONDON - Jun 20, 2025 - Elife Group, the parent company of leading ground transportation brands Elife Transfer and hoppa (including its B2B platform hoppaGo), today announced a significant expansion: the strategic integration of rail and ride-hailing services into its unified booking platforms. This transformative move strengthens the Group's comprehensive ecosystem, solidifying its position as a definitive global ground transportation marketplace for both B2C and B2B customers seeking data-driven end-to-end travel management. As a comprehensive global ground transportation marketplace, Elife Group, through Elife Transfer and hoppa, now provides seamless access to an unparalleled array of services for over 60 million travelers. Its extensive portfolio includes rail, ride-hailing, shared shuttles, private airport transportation, and charter buses. This truly seamless global travel experience spans over 2,600 airports and resorts across 182+ countries, partnering with over 70,000 global fleet providers offering over 40 diverse vehicle types. Elife Group's B2B customers, through the Elife and hoppaGo brands, can now access these enhanced multi-modal solutions through its API connectivity, white label solutions, and online booking platforms. Elife and hoppa have also introduced the ability to book cheap train tickets online with extensive global destination coverage. Elife Group now provides a single, unified online platform to search and book all ground transportation options, eliminating the need for B2C consumers to use multiple websites and for B2B partners to manage multiple relationships. By collaborating with major rail carriers like Amtrak, Heathrow Express, Stansted Express, Renfe Viajeros, and Italo, Elife Group ensures reliable and seamless access to global rail networks. Travelers can effortlessly compare rail fares and travel times, find the most affordable and fastest options, and select seat preferences where available, greatly simplifying journey planning. The Group's secure platforms facilitate bookings in minutes, delivering instant confirmation, transparent pricing, speedy e-tickets, and timely notifications. Private transfers to and from train stations further enhance convenience. Elife Group's newly launched ride-hailing services provide on-demand, flexible, and global coverage across over 182 countries and 20,000+ cities. The platform offers a wide selection of vehicles, including sedans, minivans, SUVs, and luxury cars. Travelers benefit from highly competitive pricing and rapid service, driven by real-time fare comparisons that consistently ensure the lowest fares and quickest pickups. Safety is paramount: Elife Group partners with professional, locally compliant fleet providers. All vehicles undergo rigorous maintenance, and drivers are professionally trained and certified. Real-time GPS tracking and 24/7 multilingual support further enhance passenger security. Central to Elife Group's customer-centric approach is its cutting-edge AI technology, which ensures unparalleled optimization and enhanced satisfaction. Its AI-powered smart pricing dynamically adjusts rates for competitive fares and analyzes market demand. Intelligent Order Matching algorithms optimize driver assignments and dispatch orders, significantly boosting operational efficiency and reducing idle time. Additionally, LLM-powered customer support instantly resolves inquiries and streamlines bookings by automatically extracting key details, drastically reducing response and processing times. 'This launch marks a strategic inflection point for Elife Group, hoppa and hoppaGo, fundamentally expanding our value proposition and redefining global mobility," stated Chris Harrington, Managing Director at hoppaGo. "We are moving beyond simply providing transport, we are pioneering a new era of integrated mobility, offering unparalleled end-to-end travel experiences. Our unwavering commitment to real-time price comparison, which guarantees optimal fares and expedited service, elevates value for every customer. "Elife Group is not merely a transportation provider, we are actively architecting the future of integrated global mobility for our partners," added Sayan Datta, Global VP of Sales at Elife Transfer. "Our commitment extends beyond simply providing rides. By leveraging our extensive service portfolio, advanced AI, and comprehensive fleet management capabilities, we empower businesses with scalable, reliable, and cost-effective solutions. We are eager to connect with our existing and any new customers interested in our new ride-hailing and rail solutions." About Elife Group: Elife Group is a world-leading global ground transportation marketplace, offering seamless access to an unparalleled array of services for both B2C and B2B customers. Comprising its renowned brands hoppa (including its B2B platform hoppaGo) and Elife Transfer, the Group has served over 60 million travelers worldwide. Its expansive network spans over 2,600 airports and resorts across 182+ countries, partnering with over 70,000 global fleet providers. Elife Group's comprehensive portfolio unifies all ground transport needs, including rail, ride-hailing, private transfers, shared shuttles, and charter buses, offering over 40 diverse vehicle types, from elegant 4-seater sedans to spacious 55-seater buses. Elife Group's online platforms provide a truly seamless, one-stop booking experience, ensuring customers 'arrive happy' with comprehensive, end-to-end travel solutions. Elife Group empowers B2B partners with integrated API and white-label solutions, enhancing the global travel experience through partnerships with industry leaders like Expedia, Amadeus, ETG, CWT, and Media Contact Company Name: Elife Group Contact Person: Pres Office Email: Send Email Country: United States Website:
Globe and Mail
33 minutes ago
- Globe and Mail
Could AMD Finally Challenge Nvidia With Its MI400 AI Chips?
Advanced Micro Devices (NASDAQ: AMD) has built a sizable AI accelerator business over the past few years, but it's a drop in the bucket compared with market leader Nvidia (NASDAQ: NVDA). While Nvidia's data center segment generated more than $39 billion in revenue during the most recent quarter alone, AMD managed just $5 billion in AI accelerator revenue in all of 2024. AMD's latest Instinct MI350X and MI355X graphics processing units (GPUs) are powerful, delivering four times the AI compute performance and 35 times the AI inferencing performance compared to the company's last-generation products. However, specifications and performance are in line with Nvidia's latest Blackwell-based GPUs. AMD's chips feature 288 GB of HBM3E memory and 8 terabytes per second (TB/s) of memory bandwidth, the same as Nvidia's GB300 Superchip. Raw compute performance across different types of operations is also similar to Nvidia's latest. While AMD's MI350X and MI355X are capable AI accelerators, they fail to leapfrog Nvidia. Upping the ante In 2026, AMD will release its next-generation MI400 series AI accelerators. The company claims that the flagship MI400X will be 10 times more powerful than the MI300X, an enormous leap in just a few years. The chips will feature up to 432 GB of HBM4 memory, 19.6 TB/s memory bandwidth, and significant increases in raw computing performance. Of course, Nvidia won't be sitting still. Nvidia's Vera Rubin chips are expected to ship in the second half of 2026, bringing significant performance gains over Blackwell. The initial Rubin AI accelerator will keep memory per GPU at 288 GB but up the bandwidth to 13 TB/s, while Rubin Ultra in the second half of 2027 pile on additional memory and bandwidth. Rubin is expected to more than triple compute performance over its predecessor. While companies' claims about the performance of future products should be taken with a grain of salt, AMD's MI400X looks like it will be a solid contender when it launches in 2026. It should beat Nvidia's current generation of products handily in terms of performance, although Nvidia's next-gen Rubin chips may ultimately win out. One advantage AMD will have is memory, with the MI400X set to offer more capacity and bandwidth than Rubin. For certain types of workloads, that will be appealing. In addition to MI400 family, AMD is planning to launch a new rack-scale AI solution called Helios in 2026. Helios will feature up to 72 MI400 GPUs, Venice EPYC server CPUs with up to 256 cores, and AMD's next-generation Vulcano AI network interface card to enable fast data transfer in high-density clusters. Rack-scale solutions are becoming more popular among AI infrastructure companies as they face challenges building out large enough clusters to handle the latest AI models, and Helios should be a compelling option when it launches. Nvidia will still be tough to beat While AMD will have far more powerful AI accelerators and a new rack-scale AI solution in 2026, Nvidia will probably remain the overwhelming market leader. Not only is Nvidia's hardware powerful, but the company's CUDA software ecosystem provides a critical competitive advantage. AMD is attempting to build out its own ecosystem with ROCm, and the latest version brings increased performance and new features to the platform. However, AMD continues to fight an uphill battle. AMD sees the market for AI chips reaching $500 billion by 2028. With annual AI accelerator revenue at just $5 billion for 2024, the company doesn't need to beat Nvidia to vastly grow its AI chip business over the next few years. More powerful AI chips will help, as will a more fleshed-out rack-scale solution that should appeal to the largest customers of AI accelerators. With the MI400 series and Helios slated for 2026, AMD is positioned to grow its AI-related revenue substantially over the next few years. But just like in the gaming GPU business, the company is almost certain to remain in a distant second place behind Nvidia. Should you invest $1,000 in Advanced Micro Devices right now? Before you buy stock in Advanced Micro Devices, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor 's total average return is995% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
